Filing Flows › Starling Oncology (STLN) › Q4 2025
Starling Oncology (STLN) Q4 2025 earnings results (fourth quarter 2025)
10-K filed Mar 12, 2026
Starling Oncology (STLN) reported revenue of $142M for the fourth quarter 2025 (Q4 2025), +42% from a year earlier and +4% from the quarter before. Operating margin was -4.9%, net loss $7.5M (5.3% of revenue).
Starling Oncology, Q4 2025: revenue $142M (+42% year over year), operating margin -4.9%, net loss $7.5M, operating cash flow $3.2M. The chart follows the revenue to costs, profit and cash.
| Q4 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $142M | +4% | +42% |
| Operating profit | −$6.9M | — | — |
| Net earnings | −$7.5M | — | — |
| Operating cash flow | $3.2M | — | -19% |
| Free cash flow | $2.2M | — | -3% |
What changed
Revenue was $142.0M in Q4 2025, up 42% year over year and up 4% from the previous quarter.
Operating costs exceeded revenue by $6.9M, an operating margin of -4.9%. Total costs grew 33% against revenue growth of 42%. The fastest-growing cost line was Other operating costs (+38%). The quarter ended with a net loss of $7.5M, narrower than the previous quarter's $16.5M loss.
Operating cash flow was $3.2M (down 19% year over year). Non-cash charges added back $1.6M of depreciation and amortization and $1.3M of share-based compensation. Working capital and other items added $7.8M. Capital expenditures of $1.1M left free cash flow of $2.2M.
Questions
What was Starling Oncology's revenue in the fourth quarter 2025?
Starling Oncology (STLN) reported revenue of $142M for the fourth quarter 2025 (Q4 2025), +42% from a year earlier and +4% from the quarter before.
Was Starling Oncology profitable in the fourth quarter 2025?
Operating loss was $6.9M (-4.9% of revenue) and net loss $7.5M.
Source: Starling Oncology 10-K on SEC EDGAR.